To the Editor:Hypertrophic cardiomyopathy(HCM),a genetic disorder characterized by asymmetric left ventricular hypertrophy,has an estimated prevalence of 0.5%in the general population.In patients with left ventricular...To the Editor:Hypertrophic cardiomyopathy(HCM),a genetic disorder characterized by asymmetric left ventricular hypertrophy,has an estimated prevalence of 0.5%in the general population.In patients with left ventricular outflow tract(LVOT)obstruction,the primary pathophysiological mechanism involves basal septal hypertrophy and systolic anterior motion(SAM)of the anterior mitral leaflet.Current invasive septal reduction therapies(SRT),including surgical septal myectomy(SSM)and alcohol septal ablation(ASA),aim to alleviate LVOT obstruction.Although SSM and ASA remain cornerstone treatments,emerging minimally invasive and image-guided techniques may reshape therapeutic paradigms.This article provides an overview of recent advances in the field,with a particular focus on innovations in interventional therapy.展开更多
基金This work was supported by the Zhejiang Medical Association Clinical Medical Research Funds(No.2024ZYC-Z14)Hangzhou Medicine and Health Science and Technology Funds(No.ZD20250246)
文摘To the Editor:Hypertrophic cardiomyopathy(HCM),a genetic disorder characterized by asymmetric left ventricular hypertrophy,has an estimated prevalence of 0.5%in the general population.In patients with left ventricular outflow tract(LVOT)obstruction,the primary pathophysiological mechanism involves basal septal hypertrophy and systolic anterior motion(SAM)of the anterior mitral leaflet.Current invasive septal reduction therapies(SRT),including surgical septal myectomy(SSM)and alcohol septal ablation(ASA),aim to alleviate LVOT obstruction.Although SSM and ASA remain cornerstone treatments,emerging minimally invasive and image-guided techniques may reshape therapeutic paradigms.This article provides an overview of recent advances in the field,with a particular focus on innovations in interventional therapy.
